Ovarian Cancer Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Diagnosis Type (Biopsy, MRI scan, CT scan, PET Scan, Ultrasound, Blood Test, Others), By Disease Type (Stromal Tumour, Germ Cell Tumour, Epithelial Tumour, Primary Peritoneal Carcinoma), By End-User (Hospitals, Clinics, Diagnostic Centres, Others) and Region

Ovarian Cancer Diagnostics Market size was valued at US$ 2.6 billion in 2023 and is poised to grow at a CAGR of 8.8% from 2024-2030. Ovarian Cancer is an abnormal growth of cells that forms in the tissues of the ovary that further multiplies and invades and destroys healthy body tissues. The pelvic exam, imaging tests, blood tests, surgery, and other treatments are among those used for diagnosing ovarian cancer. The majority of cases of ovarian cancer occur in women between the ages of 55 and above. As the world's geriatric population rises and early detection and treatment are given more importance, it is getting more common, which is anticipated to hasten the development of the market.

According to World Cancer Research Fund International, Ovarian cancer is the 8^th most common cancer in women worldwide with about 313,000 new cases in 2020 thus its diagnosis becomes important and further increases the market. The increasing awareness about early cancer detection as well as changes in lifestyle choices like smoking, drinking, and obesity are currently driving the market. Moreover, the increase in the development of low-cost effective cancer diagnostic devices like CryoPop®, LumaGEM®, MarginProbe®, and picture archiving and communication systems (PACS) have opened up several opportunities for market growth. Based on the procedure type, biopsy tests are most relevant and are used extensively. Liquid biopsy is the most used and accurate detection technique. For instance, in June 2023, LabCorp launched a new liquid biopsy to detect cancer-related biomarkers.

Increasing R&D activities, rising healthcare expenditure, increasing health insurance coverages, and activities by non-governmental organizations (NGOs) also propel market growth. For instance, the “World Ovarian Cancer Coalition Atlas 2020” initiative was launched for raising awareness among the population. But the high cost of cancer diagnosis and treatment and insufficient knowledge and awareness among the female population of developing and under-developing countries hinder the growth of the market. Moreover, the lack of skilled professionals may hinder the detection and treatment of the patient and thus, may hamper the market growth. However, the initiatives taken by several governments, increasing healthcare spending, developing technology and instrumentation, increasing competition between key players, and developing infrastructure are expected to accelerate ovarian cancer diagnostic market development.

Ovarian Cancer Diagnostics Market Key Developments

• In April 2018, Boston Scientific acquired nVision Medical Corporation, a privately held company focused on women’s health. nVision developed the first and only device in the U.S. that cleared the FDA providing a platform for earlier diagnosis of ovarian cancer.
• In December 2022, PredOmix launched a one-of-its-kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with 98% accuracy.
• In November 2021, U.S. Food and Drug Administration approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions.